The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder
Authors:
- Heinz GrunzeHGHeinz Grunze
- Eduard VietaEduard Vieta
- Sergey MosolovSMSergey Mosolov
- On Behalf Of The Members Of The Wfsbp Task Force On Bipolar Affective Disorders Working On This TopicOTOn Behalf Of The Members Of The Wfsbp Task Force On Bipolar Affective Disorders Working On This Topic
- 3 November 2017
- journal article
- research article
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 19 (1) , 2-58
Abstract
Objectives: Although clinically highly relevant, the recognition and treatment of bipolar mixed states has played only an underpart in recent guidelines. This WFSBP guideline has been developed to supply a systematic overview of all scientific evidence pertaining to the acute and long-term treatment of bipolar mixed states in adults. Methods: Material used for these guidelines is based on a systematic literature search using various data bases. Their scientific rigour was categorised into six levels of evidence (A–F), and different grades of recommendation to ensure practicability were assigned. We examined data pertaining to the acute treatment of manic and depressive symptoms in bipolar mixed patients, as well as data pertaining to the prevention of mixed recurrences after an index episode of any type, or recurrence of any type after a mixed index episode. Results: Manic symptoms in bipolar mixed states appeared responsive to treatment with several atypical antipsychotics, the best evidence resting with olanzapine. For depressive symptoms, addition of ziprasidone to treatment as usual may be beneficial; however, the evidence base is much more limited than for the treatment of manic symptoms. Besides olanzapine and quetiapine, valproate and lithium should also be considered for recurrence prevention. Limitations: The concept of mixed states changed over time, and recently became much more comprehensive with the release of DSM-5. As a consequence, studies in bipolar mixed patients targeted slightly different bipolar subpopulations. In addition, trial designs in acute and maintenance treatment also advanced in recent years in response to regulatory demands. Conclusions: Current treatment recommendations are still based on limited evidence, and there is a clear demand for confirmative studies adopting the DSM-5 specifier with mixed features concept.Keywords
This publication has 308 references indexed in Scilit:
- DSM-5 mixed specifier for manic episodes: Evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial dataJournal of Affective Disorders, 2013
- The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double‐blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144)Bipolar Disorders, 2012
- Sponsors’ participation in conduct and reporting of industry trials: a descriptive studyTrials, 2012
- A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed StatePLOS ONE, 2012
- Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profilesEuropean Neuropsychopharmacology, 2012
- Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I DisorderThe Journal of Clinical Psychiatry, 2011
- Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trialsBMC Psychiatry, 2011
- Depression symptom ratings in geriatric patients with bipolar maniaInternational Journal of Geriatric Psychiatry, 2011
- Dissimilar morbidity following initial mania versus mixed-states in type-I bipolar disorderJournal of Affective Disorders, 2010
- Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months – European mania in bipolar longitudinal evaluation of medicationBMC Psychiatry, 2009